8	O
.	O
2	O
.	O

Species	O
Differences	O
in	O
PPARalpha	O
-	O
Associated	O
Signaling	O

The	O
PPARalpha	O
isotype	O
has	O
prime	O
importance	O
for	O
studies	O
with	O
animal	O
models	O
to	O
predict	O
the	O
effects	O
of	O
hepatic	B-Organ
PPs	O
in	O
humans	O
,	O
because	O
PPARalpha	O
agonists	O
induce	O
seemingly	O
quite	O
different	O
actions	O
in	O
rodents	O
and	O
humans	O
[	O
53	O
]	O
.	O

Originally	O
,	O
as	O
the	O
name	O
indicates	O
,	O
PPARs	O
were	O
studied	O
because	O
of	O
their	O
ability	O
to	O
bind	O
PPs	O
and	O
consequently	O
induce	O
PP	O
-	O
metabolizing	O
enzymes	O
.	O

In	O
rats	O
and	O
mice	O
,	O
but	O
not	O
in	O
humans	O
,	O
PPs	O
such	O
as	O
hypolipidemic	O
drugs	O
,	O
industrial	O
plasticizers	O
,	O
and	O
herbicides	O
are	O
non	O
-	O
genotoxic	O
carcinogens	O
that	O
cause	O
liver	B-Cancer
tumors	I-Cancer
[	O
54	O
]	O
.	O

In	O
humans	O
,	O
these	O
drugs	O
function	O
to	O
maintain	O
lipid	O
homeostasis	O
and	O
do	O
not	O
induce	O
peroxisome	B-Cellular_component
proliferation	O
.	O

Thus	O
,	O
the	O
toxicity	O
and	O
carcinogenicity	O
of	O
PPs	O
are	O
highly	O
species	O
specific	O
[	O
55	O
]	O
.	O

The	O
species	O
differences	O
may	O
be	O
attributable	O
to	O
lower	O
PPAR	O
mRNA	O
expression	O
levels	O
in	O
h	B-Cell
-	I-Cell
hepatocytes	I-Cell
compared	O
with	O
rodent	O
cells	B-Cell
[	O
56	O
,	O
57	O
]	O
.	O

Alternatively	O
,	O
or	O
additionally	O
,	O
species	O
differences	O
may	O
be	O
the	O
result	O
of	O
different	O
sensitivities	O
of	O
the	O
genes	O
associated	O
with	O
the	O
peroxisome	B-Cellular_component
proliferation	O
response	O
to	O
low	O
levels	O
of	O
PPs	O
,	O
owing	O
to	O
structural	O
differences	O
in	O
PPARalpha	O
[	O
54	O
]	O
.	O

There	O
are	O
both	O
similarities	O
and	O
differences	O
in	O
responses	O
to	O
xenobiotics	O
among	O
not	O
only	O
different	O
species	O
(	O
interspecies	O
)	O
but	O
also	O
individuals	O
of	O
the	O
same	O
species	O
(	O
intraspecies	O
)	O
.	O

Interspecific	O
PPARalpha	O
diversity	O
between	O
rodents	O
and	O
humans	O
is	O
well	O
known	O
and	O
has	O
been	O
studied	O
with	O
respect	O
to	O
drug	O
metabolism	O
.	O

NR	O
subfamily	O
1	O
members	O
have	O
at	O
least	O
two	O
functions	O
in	O
mammals	O
.	O

One	O
is	O
to	O
regulate	O
peroxisome	B-Cellular_component
proliferation	O
through	O
binding	O
to	O
PPAR	O
response	O
elements	O
(	O
PPREs	O
)	O
in	O
the	O
promoters	O
of	O
genes	O
such	O
as	O
ACO	O
[	O
58	O
,	O
59	O
]	O
,	O
bifunctional	O
dehydrogenase	O
/	O
hydratase	O
(	O
BFE	O
)	O
[	O
60	O
]	O
,	O
and	O
microsomal	O
CYP4A1	O
[	O
61	O
]	O
.	O

The	O
other	O
is	O
to	O
modulate	O
the	O
serum	B-Organism_substance
cholesterol	O
level	O
by	O
targeting	O
genes	O
such	O
as	O
the	O
lipoprotein	O
lipase	O
gene	O
[	O
62	O
]	O
and	O
the	O
apolipoprotein	O
regulating	O
genes	O
AI	O
,	O
AII	O
,	O
and	O
CII	O
[	O
63	O
]	O
.	O

The	O
former	O
mechanism	O
appears	O
to	O
function	O
in	O
rodents	O
,	O
but	O
not	O
in	O
humans	O
,	O
and	O
is	O
responsible	O
for	O
the	O
induction	O
of	O
peroxisome	B-Cellular_component
proliferation	O
and	O
hepatocarcinogenesis	O
,	O
whereas	O
the	O
latter	O
mechanism	O
controls	O
basic	O
lipid	O
metabolism	O
in	O
both	O
rodents	O
and	O
humans	O
[	O
56	O
]	O
.	O

This	O
species	O
difference	O
in	O
xenobiotic	O
receptor	O
/	O
ligand	O
signaling	O
may	O
be	O
attributable	O
to	O
differences	O
in	O
the	O
expression	O
level	O
of	O
a	O
receptor	O
,	O
or	O
to	O
differences	O
in	O
receptor	O
/	O
ligand	O
binding	O
affinity	O
,	O
and	O
causes	O
difficulty	O
in	O
determining	O
responses	O
in	O
humans	O
based	O
on	O
rodent	O
data	O
[	O
56	O
]	O
.	O

